Considering gefitinib’s role as a prevalent NSCLC therapy, we assessed its sensitivity correlation within the TCGA-LUAD dataset, pinpointing five primary genes: CHEK2, ITGB4, RRM2, GAPDH, and KRT18, as listed in Supplementary Table 6. This evidence concerns the gene KRT18 and non-small cell lung carcinoma.